SynthesisAllergy2023
Biomarkers associated with the development of comorbidities in patients with atopic dermatitis: A systematic review.
Synthesis in Allergy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Pooled it
- Biomarkers associated with the development of comorbidities in patients with atopic dermatitis: A systematic review.Allergy · 2023Pooled it
- Review
- An AI-augmented review of childhood atopic dermatitis biomarkers across genetic, immune, microbial, and metabolic domains.Molecular medicine (Cambridge, Mass.) · 2026Review
- Untangling the Complexity of Childhood Atopic Dermatitis: Phenotypes and Endotypes.Clinical reviews in allergy & immunology · 2026Review
- Ethical challenges in biomarker research and precision medicine - a qualitative study in dermatology.BMC medical ethics · 2025Article
- Advances in Atopic Dermatitis Treatment: From Pathogenesis to Natural Product-Based Therapies.Phytotherapy research : PTR · 2025Review
- CHN1 as a potential predictive genetic biomarker for atopic dermatitis-related depression.Frontiers in immunology · 2025Article
- Defining disease severity in atopic dermatitis and psoriasis for the application to biomarker research: an interdisciplinary perspective.The British journal of dermatology · 2024Review
- Tape Stripping - Searching for Minimally Invasive Biomarkers in Atopic Dermatitis.Dermatology practical & conceptual · 2024Review
- Exploring the Complexities of Atopic Dermatitis: Pathophysiological Mechanisms and Therapeutic Approaches.Journal of biotechnology and biomedicine · 2024Article
- Atopic March or Atopic Multimorbidity-Overview of Current Research.Medicina (Kaunas, Lithuania) · 2023Review
- The origins and longevity of IgE responses as indicated by serological and cellular studies in mice and humans.Allergy · 2023Review
- A concept for integrated care pathways for atopic dermatitis-A GAClinical and translational allergy · 2023Review
- Disease modification in inflammatory skin disorders: opportunities and challenges.Nature reviews. Drug discovery · 2023Review
- [Molecular diagnosis of hand eczema].Dermatologie (Heidelberg, Germany) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomarkers associated with the development of comorbidities in atopic dermatitis (AD) patients have been reported, but have not yet been systematically reviewed. Seven electronic databases were searched, from database inception to September 2021. English language randomized controlled trials, prospective and retrospective cohort, and case-control studies that investigated the association between a biomarker and the development of comorbidities in AD patients were included. Two authors independently screened the records for eligibility, one extracted all data, and critically appraised the quality of studies and risk of bias. Fifty six articles met the inclusion criteria, evaluating 146 candidate biomarkers. The most frequently reported biomarkers were filaggrin mutations and allergen specific-IgE. Promising biomarkers include specific-IgE and/or skin prick tests predicting the development of asthma, and genetic polymorphisms predicting the occurrence of eczema herpeticum. The identified studies and biomarkers were highly heterogeneous, and associated with predominately moderate-to-high risk of bias across multiple domains. Overall, findings were inconsistent. High-quality studies assessing biomarkers associated with the development of comorbidities in people with AD are lacking. Harmonized datasets and independent validation studies are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.